a generic version of Sprycel® 1, in the United States, with 180-days of exclusivity. Apotex 50th Anniversary Logo (CNW Group/Apotex Corp.) Dasatinib is a kinase inhibitor used to treat certain ...

Second-generation tyrosine kinase inhibitor approved for children with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase. Bristol-Myers Squibb announced that the Food and ...

PRINCETON, N.J. & TOKYO--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYSE: BMY) and Otsuka Pharmaceutical Co., Ltd. today announced the launch of My SPRYCEL ® (dasatinib) Support, a useful ...

However, the new drugs may replace Gleevec in newly diagnosed patients. Giving Tasigna (nilotinib) or Sprycel (dasatinib) to previously untreated CML patients resulted in faster, better responses ...

PRINCETON, N.J. & TOKYO--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYSE:BMY) and Otsuka Pharmaceutical Co., Ltd. today announced Phase III study results in which SPRYCEL (dasatinib ...

Bristol-Myers Squibb CompanyBMY announced that the European Commission (EC) has approved its oncology drug Sprycel (dasatinib) in combination with chemotherapy for the treatment of pediatric ...

Dasatinib (Sprycel) Granted Full Approval for Chronic Myeloid Leukemia On May 21, the FDA granted full approval for dasatinib tablets (Sprycel; Bristol-Myers Squibb Co) for the treatment of adults ...

The filing is based on the results of the DASISION trial. SPRYCEL, an oral BCR-ABL inhibitor, is currently approved by the FDA for the treatment of adults for all phases of CML (chronic ...

PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYSE:BMY) and Otsuka America Pharmaceutical, Inc. today announced five-year follow-up results from a Phase 3 randomized, open-label ...

This decision does not impact our patents outside of the EU or other Sprycel-related patents. BMS has a long-standing heritage in oncology. Sprycel will continue to be a significant asset in our ...